Daprodustat contraindications and unsuitable groups

Daprodustat (Daprodustat), as a new oral erythropoietin production drug, has shown good efficacy in chronic kidney disease (CKD)-related anemia, but not all patients are suitable for use. Drug contraindications mainly involve drug interactions and poor control of underlying diseases. First, daprostat should be avoided in patients receiving strong CYP2C8 inhibitors, such as gemfibrozil. This type of drug may significantly affect the metabolism of daprostat, leading to an abnormal increase in blood concentration, thus increasing the risk of adverse reactions. In clinical practice, doctors should carefully evaluate patients' drug history to avoid potential drug interactions.

Secondly, dapostat is not suitable for patients whose hypertension is not effectively controlled. Due to the possible effects of this drug on hemodynamic parameters, patients with unstable blood pressure may be at increased risk of cardiovascular events during use. Before starting treatment, the patient's blood pressure should be ensured to be within a controllable range, and the antihypertensive regimen should be continuously monitored and adjusted during medication. In addition, clinicians need to carefully assess the risks and benefits for patients with preexisting severe cardiovascular disease, active thrombosis, or bleeding tendencies.

In addition, its use is not recommended for pregnant women, lactating women, and patients allergic to daprestat or its ingredients. In these special populations, the drugs may pose unknown risks, and clinical data are limited. For children and adolescent patients, there is currently a lack of sufficient safety and efficacy studies, so routine use is not recommended.

By strictly adhering to contraindications and user restrictions, clinicians can maximize the efficacy of daprostat in the treatment of anemia in chronic kidney disease while ensuring safety, while reducing the incidence of adverse events. This can also help develop a personalized treatment plan for patients, improving hemoglobin control and quality of life.

Reference materials:https://en.wikipedia.org/wiki/Daprodustat